SCHEMBL23934287

SCHEMBL23934287

CN1C(=O)c2cc(NC(=O)c3ccc(Cl)s3)cc(N)c2C1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.54
NPSR1 Q6W5P4 2/20 0.54
RXFP1 Q9HBX9 1/20 0.54
ALDH1A1 P00352 10/20 0.43
NPC1 O15118 8/20 0.43
RAB9A P51151 8/20 0.43
SMN1; SMN2 Q16637 6/20 0.43
KMT2A Q03164 9/20 0.43
MEN1 O00255 8/20 0.43
HPGD P15428 5/20 0.43
NFKB1 P19838 4/20 0.43
NFKB2 Q00653 4/20 0.43
RELA Q04206 4/20 0.43
TP53 P04637 2/20 0.43
MAPT P10636 4/20 0.41
MAPK1 P28482 2/20 0.41
LMNA P02545 1/20 0.41
CASP1 P29466 1/20 0.40
CASP7 P55210 1/20 0.40
POLB P06746 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23934204 0.88 KDM4E (0.54) KDM4ENPSR1RXFP1ALDH1A1NPC1
SCHEMBL23934271 0.82 KDM4E (0.68) KDM4ENPSR1RXFP1ALDH1A1NPC1
SCHEMBL23934267 0.77 HPGD (0.53) KDM4ENPSR1RXFP1ALDH1A1NPC1
SCHEMBL27099939 0.77 POLB (0.50) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL23934285 0.77 ACE2 (0.48) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL27099941 0.75 ALDH1A1 (0.41) KDM4ERXFP1ALDH1A1KMT2AMEN1
SCHEMBL27099938 0.74 KMT2A (0.49) KDM4ENPSR1ALDH1A1SMN1; SMN2KMT2A
SCHEMBL27100055 0.73 ALOX15 (0.47) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL23934284 0.72 MAPT (0.53) ALDH1A1NPC1RAB9AKMT2AMEN1
SCHEMBL27100057 0.72 CA12 (0.49) KDM4ERXFP1ALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics XAVIER UNIVERSITY OF LOUISIANA (US) 2024-02-27 US disclosed
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS XAVIER UNIVERSITY OF LOUISIANA 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS RPS6KA6, RPS6KA1, RPS6KA3 KDM4E 1367/4885NPSR1 2238/4885RXFP1 2817/4885
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics RPS6KA6, RPS6KA1, RPS6KA3 KDM4E 1367/4885NPSR1 2238/4885RXFP1 2817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.